Biodexa Pharmaceuticals Statistics
Share Statistics
Biodexa Pharmaceuticals has 580.84K shares outstanding. The number of shares has increased by 145.59% in one year.
| Shares Outstanding | 580.84K |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 48.84% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 2.45B |
| Failed to Deliver (FTD) Shares | 14 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 27.81K, so 4.79% of the outstanding shares have been sold short.
| Short Interest | 27.81K |
| Short % of Shares Out | 4.79% |
| Short % of Float | 0% |
| Short Ratio (days to cover) | 0.08 |
Valuation Ratios
The PE ratio is -0.24 and the forward PE ratio is null.
| PE Ratio | -0.24 |
| Forward PE | null |
| PS Ratio | 4.37 |
| Forward PS | 158659.2 |
| PB Ratio | 0.36 |
| P/FCF Ratio | -0.23 |
| PEG Ratio | n/a |
Enterprise Valuation
Biodexa Pharmaceuticals has an Enterprise Value (EV) of -3.84M.
| EV / Earnings | 0.54 |
| EV / Sales | -10.09 |
| EV / EBITDA | 0.54 |
| EV / EBIT | 0.48 |
| EV / FCF | 0.54 |
Financial Position
The company has a current ratio of 1.26, with a Debt / Equity ratio of 0.
| Current Ratio | 1.26 |
| Quick Ratio | 1.26 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -195.46 |
Financial Efficiency
Return on equity (ROE) is -1.51% and return on capital (ROIC) is -147.4%.
| Return on Equity (ROE) | -1.51% |
| Return on Assets (ROA) | -0.67% |
| Return on Capital (ROIC) | -147.4% |
| Revenue Per Employee | 18.14K |
| Profits Per Employee | -337.10K |
| Employee Count | 21 |
| Asset Turnover | 0.04 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -406.00K |
| Effective Tax Rate | 0.05 |
Stock Price Statistics
The stock price has increased by -91.14% in the last 52 weeks. The beta is 1.44, so Biodexa Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.44 |
| 52-Week Price Change | -91.14% |
| 50-Day Moving Average | 4.69 |
| 200-Day Moving Average | 15.2 |
| Relative Strength Index (RSI) | 45.09 |
| Average Volume (20 Days) | 289.24K |
Income Statement
In the last 12 months, Biodexa Pharmaceuticals had revenue of 381.00K and earned -7.08M in profits. Earnings per share was -224.13.
| Revenue | 381.00K |
| Gross Profit | -3.69M |
| Operating Income | -8.01M |
| Net Income | -7.08M |
| EBITDA | -7.16M |
| EBIT | -8.01M |
| Earnings Per Share (EPS) | -224.13 |
Balance Sheet
The company has 5.97M in cash and 464.00K in debt, giving a net cash position of 5.51M.
| Cash & Cash Equivalents | 5.97M |
| Total Debt | 464.00K |
| Net Cash | 5.51M |
| Retained Earnings | -144.77M |
| Total Assets | 13.97M |
| Working Capital | 4.04M |
Cash Flow
In the last 12 months, operating cash flow was -6.83M and capital expenditures -263.00K, giving a free cash flow of -7.09M.
| Operating Cash Flow | -6.83M |
| Capital Expenditures | -263.00K |
| Free Cash Flow | -7.09M |
| FCF Per Share | -224.44 |
Margins
Gross margin is -967.45%, with operating and profit margins of -2.10K% and -1.86K%.
| Gross Margin | -967.45% |
| Operating Margin | -2.10K% |
| Pretax Margin | -1.96K% |
| Profit Margin | -1.86K% |
| EBITDA Margin | -1.88K% |
| EBIT Margin | -2.10K% |
| FCF Margin | -1.86K% |
Dividends & Yields
BDRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -5323.75% |
| FCF Yield | -0.72% |
Analyst Forecast
The average price target for BDRX is $200, which is 4650.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $200 |
| Price Target Difference | 4650.6% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Oct 4, 2024. It was a backward split with a ratio of 1:25.
| Last Split Date | Oct 4, 2024 |
| Split Type | backward |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | 103.67 |
| Piotroski F-Score | 1 |